Cantor Fitzgerald Reaffirms Their Buy Rating on Centene (CNC)

In a report released yesterday, Sarah James from Cantor Fitzgerald maintained a Buy rating on Centene (CNC – Research Report), with a price target of $90.00. The company’s shares closed yesterday at $67.71.

James covers the Healthcare sector, focusing on stocks such as UnitedHealth, CVS Health, and Humana. According to TipRanks, James has an average return of 10.6% and a 62.98% success rate on recommended stocks.

In addition to Cantor Fitzgerald, Centene also received a Buy from Wells Fargo’s Steve Baxter in a report issued on June 5. However, on May 29, Robert W. Baird initiated coverage with a Hold rating on Centene (NYSE: CNC).

The company has a one-year high of $81.42 and a one-year low of $60.83. Currently, Centene has an average volume of 3.51M.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Centene (CNC) Company Description:

Centene Corporation is a diversified healthcare company that primarily engages in providing programs and services to the government sponsored healthcare programs. The company is also engaged in providing education and outreach programs to assist members in accessing quality and appropriate healthcare services.